DOTAMTATE

DOTAMTATE is a somatostatin analogue. DOTAMTATE marked 212Pb is promising for research of somatostatin receptor positive neuroendocrine tumors[1].

Product Specifications

CAS Number

[2415661-92-4]

UNSPSC

12352209

Target

Drug Derivative

Related Pathways

Others

Field of Research

Cancer

Purity

99.55

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)NC([C@H](NC(CN2CCN(CCN(CCN(CC2)CC(N)=O)CC(N)=O)CC(N)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(C=C4)O)N[C@@H]1CC5=CNC6=CC=CC=C56

Molecular Formula

C65H93N17O16S2

Molecular Weight

1432.67

References & Citations

[1]Stallons et al. Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model. Mol Cancer Ther. 2019 May;18 (5) :1012-1021.